Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Last trade$2.11
Day change-$0.055 (-2.55%)
Day range$2.04 – $2.24
Volume1,266,177
Market cap$241M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$241.19M
Price / earnings
—
Price / book
0.74×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.07×
Profitability
Earnings per share
-$0.14
Return on assets
-3.85%
Return on equity
-4.94%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.16×
Current ratio
7.26×
Quick ratio
7.25×
Cash ratio
2.49×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$159.23M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RCKT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$19.79M
$17.43M
$17.06M
$14.68M
$18.35M
$25.02M
$28.45M
$25.34M
Research and development
$31.17M
$29.5M
$31.45M
$29.35M
$34.07M
$42.66M
$35.94M
$37.36M
Total operating expenses
$50.97M
$46.92M
$48.51M
$43.96M
$52.25M
$71.15M
$64.39M
$62.69M
Operating income
-$50.97M
-$46.92M
-$48.51M
-$43.96M
-$52.25M
-$71.15M
-$64.39M
-$62.69M
Interest expense
-$473K
-$473K
-$473K
-$473K
-$473K
-$473K
-$472K
-$473K
Income before taxes
-$49.18M
$131.84M
-$48.82M
-$42.54M
-$50.33M
-$68.92M
-$63.52M
-$60.33M
Income taxes
$54K
$8.62M
$0
$0
$0
$0
$0
$0
Net income
-$49.23M
$123.21M
-$48.82M
-$42.54M
-$50.33M
-$68.92M
-$63.52M
-$60.33M
Net income attributable to common shareholders
-$49.23M
$123.21M
-$47.59M
-$42.54M
-$50.33M
-$68.92M
-$61.33M
-$60.33M
EBITDA
-$49.47M
-$45.36M
-$46.9M
-$42.35M
-$49.72M
-$65.64M
-$61.94M
-$60.87M
Basic earnings per share
-$0.43
$1.09
-$0.42
-$0.38
-$0.45
-$0.62
-$0.56
-$0.62
Diluted earnings per share
-$0.43
$1.08
-$0.42
-$0.38
-$0.45
-$0.62
-$0.56
-$0.62
Recent news
Company coverage with links to the original publishers.
Law firm investigating Rocket Pharmaceuticals for potential securities fraud related to undisclosed clinical trial protocol changes and serious adverse events in RP-A501 study, which led to a 37% stock price drop.
Law firm alerts investors about potential securities fraud class action lawsuits for four companies, alleging misleading statements and undisclosed risks during specific class periods in 2024-2025.
Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements regarding the effectiveness and safety of drug candidate RP-A501, with an important deadline on August 11, 2025.
Law Offices of Frank R. Cruz alerts investors about an upcoming August 11, 2025 deadline to participate in a securities fraud class action lawsuit against Rocket Pharmaceuticals following an FDA clinical hold on a Danon disease treatment trial after a patient's death.
Rocket Pharmaceuticals faces a class action lawsuit alleging misleading statements about its Phase 2 clinical trial for RP-A501, with claims of concealing serious adverse events including patient death, which led to an FDA clinical hold and stock price decline.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.